🏛️ Verified NIH Record • Updated 2026-03-27

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (NCT03157128)

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic of Scottsdale — Scottsdale, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (85 Sites)

  • Mayo Clinic of Scottsdale — Scottsdale, Arizona
  • City of Hope National Medical Center — Duarte, California
  • UCLA Medical Center — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
  • Kaiser Permanente — Oakland, California
  • Irvine Medical Center — Orange, California
  • University of California - San Diego — San Diego, California
  • UCSF Medical Center at Mission Bay — San Francisco, California
  • Kaiser Permanente Medical Center — Walnut Creek, California
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
  • Yale Cancer Center — New Haven, Connecticut
  • Mayo Clinic in Florida — Jacksonville, Florida
  • Memorial Hospital Pembroke — Pembroke, Florida
  • Emory University — Atlanta, Georgia
  • University of Chicago Medicine-Comprehensive Cancer Center — Chicago, Illinois
  • Ochsner Clinic Foundation — New Orleans, Louisiana
  • University of Maryland Medical Center — Baltimore, Maryland
  • Johns Hopkins University — Baltimore, Maryland
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • University of Michigan — Ann Arbor, Michigan
  • START Midwest — Grand Rapids, Michigan
  • Mayo Clinic — Rochester, Minnesota
  • Washington University Medical School — St Louis, Missouri
  • Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗